180 related articles for article (PubMed ID: 22825337)
21. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
22. Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Xin Y; Shen XD; Cheng L; Hong DF; Chen B
Cancer Chemother Pharmacol; 2014 Apr; 73(4):711-9. PubMed ID: 24519751
[TBL] [Abstract][Full Text] [Related]
23. mTORC1 inhibition increases neurotensin secretion and gene expression through activation of the MEK/ERK/c-Jun pathway in the human endocrine cell line BON.
Li J; Liu J; Song J; Wang X; Weiss HL; Townsend CM; Gao T; Evers BM
Am J Physiol Cell Physiol; 2011 Jul; 301(1):C213-26. PubMed ID: 21508335
[TBL] [Abstract][Full Text] [Related]
24. The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53.
Lee SO; Andey T; Jin UH; Kim K; Singh M; Safe S
Oncogene; 2012 Jul; 31(27):3265-76. PubMed ID: 22081070
[TBL] [Abstract][Full Text] [Related]
25. The Effect of LKB1 Activity on the Sensitivity to PI3K/mTOR Inhibition in Non-Small Cell Lung Cancer.
Shukuya T; Yamada T; Koenig MJ; Xu J; Okimoto T; Li F; Amann JM; Carbone DP
J Thorac Oncol; 2019 Jun; 14(6):1061-1076. PubMed ID: 30825612
[TBL] [Abstract][Full Text] [Related]
26. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
Koo J; Yue P; Gal AA; Khuri FR; Sun SY
Cancer Res; 2014 May; 74(9):2555-68. PubMed ID: 24626091
[TBL] [Abstract][Full Text] [Related]
27. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
28. Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Le Grand M; Berges R; Pasquier E; Montero MP; Borge L; Carrier A; Vasseur S; Bourgarel V; Buric D; André N; Braguer D; Carré M
Sci Rep; 2017 Mar; 7():45136. PubMed ID: 28332584
[TBL] [Abstract][Full Text] [Related]
29. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
30. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Chandarlapaty S; Sawai A; Scaltriti M; Rodrik-Outmezguine V; Grbovic-Huezo O; Serra V; Majumder PK; Baselga J; Rosen N
Cancer Cell; 2011 Jan; 19(1):58-71. PubMed ID: 21215704
[TBL] [Abstract][Full Text] [Related]
31. AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers.
Huang W; Yang L; Liang S; Liu D; Chen X; Ma Z; Zhai S; Li P; Wang X
Dig Dis Sci; 2013 Oct; 58(10):2873-80. PubMed ID: 23912246
[TBL] [Abstract][Full Text] [Related]
32. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
33. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Momota H; Nerio E; Holland EC
Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
[TBL] [Abstract][Full Text] [Related]
34. Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury.
Mariappan MM; Prasad S; D'Silva K; Cedillo E; Sataranatarajan K; Barnes JL; Choudhury GG; Kasinath BS
J Biol Chem; 2014 Dec; 289(51):35363-75. PubMed ID: 25339176
[TBL] [Abstract][Full Text] [Related]
35. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
Sokolosky M; Chappell WH; Stadelman K; Abrams SL; Davis NM; Steelman LS; McCubrey JA
Cell Cycle; 2014; 13(5):820-33. PubMed ID: 24407515
[TBL] [Abstract][Full Text] [Related]
38. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
Zhang B; Wang L; Zhang Q; Yan Y; Jiang H; Hu R; Zhou X; Liu X; Feng J; Lin N
Mol Oncol; 2019 Apr; 13(4):946-958. PubMed ID: 30663221
[TBL] [Abstract][Full Text] [Related]
39. PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.
Ling YH; Aracil M; Zou Y; Yuan Z; Lu B; Jimeno J; Cuervo AM; Perez-Soler R
Clin Cancer Res; 2011 Aug; 17(16):5353-66. PubMed ID: 21690574
[TBL] [Abstract][Full Text] [Related]
40. Combination of the LARS1 Inhibitor, BC-LI-0186 with a MEK1/2 Inhibitor Enhances the Anti-Tumor Effect in Non-Small Cell Lung Cancer.
Lee SH; Kim EY; Han JM; Han G; Chang YS
Cancer Res Treat; 2023 Jul; 55(3):851-864. PubMed ID: 36960627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
